Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease

Behavioural Neurology

Volumn 11, Issue 4, 1998, Pages 211-216

  Rösler, Michael ^a   Retz, Wolfgang ^a   Retz Junginger, P ^a   Dennler, Hans Joachim ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b Novartis Pharma GmbH   (Germany)

Author keywords

Alzheimer's disease; Behavioural symptoms; Cholinesterase inhibitors; CIBIC Plus; Rivastigmine

Indexed keywords

BENZODIAZEPINE; CHOLINESTERASE INHIBITOR; HALOPERIDOL; RIVASTIGMINE;

ADULT; ADVERSE DRUG REACTION; AGED; AGGRESSION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CAREGIVER; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; FEMALE; GERMANY; HALLUCINATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; PARANOIA; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT OUTCOME;

EID: 0141799784     PISSN: 09534180     EISSN: None     Source Type: Journal    
DOI: 10.1155/1999/168023     Document Type: Article

References (19)

1. R. Anand and G. Gharabawi, Clinical development of Exelon (ENA-713): the ADENA programme, J. Drug Dev. Clin. Pract. 8 (1996), 9-14.
2. N.C. Bodick, W.W. Offen, A.I. Levey, N.R. Cutler, S.G. Ga-thier, A. Satlin, H.E. Shannon, G.D. Tollefson, K. Rasmussen, F.P. Bymaster, D.J. Hurley, W.Z. Potter and S.M. Paul, Effects of Xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioural symptoms in Alzheimer disease, Arch. Neurol. 54 (1997), 465-473.
3. A. Burns, R. Jacoby and R. Levy, Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behaviour, Br. J. Psychiatry 157 (1990), 86-94.
4. J.L. Cummings, D.G. Gorman and J. Shapira, Physostigmine ameliorates the delusions of Alzheimer's disease, Biol. Psychiatry 33 (1993), 536-541.
5. J.L. Cummings and D. Kaufer, Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited, Neurology 47 (1996), 876-883.
6. J.L. Cummings and C. Back, The cholinergic hypothesis of neuropsychiatrie symptoms in Alzheimer's disease, Am. J. Geriatr. Psychiatry 6 (1998), S64-S78.
7. W. Gsell, I. Strein and P. Riederer, The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared, J. Neural Transm. Suppl. 47 (1996), 73-101.
8. D.S. Janowsky, S.C. Risch and J.C. Gillin, Adrenergic-cholinergic balance and the treatment of affective disorders, Prog. Neuropsychopharmacol. Biol. Psychiatry 7 (1983), 297-307.
9. D. Kaufer, J.L. Cummings and D. Christine, Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity, J. Neuropsychiatry Clin. Neurosci. 10 (1998), 55-63.
10. M.S. Mega, J.L. Cummings, T. Fiorello and J. Gornbein, The spectrum of behavioural changes in Alzheimer's disease, Neurology 46 (1996), 130-135.
11. E. Perry, C. Ballard, D. Spurden, A. Cheng, M. Johnson, I. McKeith, M. Piggott and R. Perry, Cholinergic systems in the human brain: psychopharmacology and psychosis, Alz. Dis. Rev. 3 (1998), 117-124.
12. R.J. Polinsky, Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, Clin. Ther. 20 (1998), 634-647.
13. R.A. Pruchno and N.L. Resch, Aberrant behaviors and Alzheimer's disease: mental health effects on spouse caregivers, J. Gerontol. 44 (1989), S177-182.
14. P.V. Rabins, N.L. Mace and M.J. Lucas, The impact of dementia on the family, J. A. M. A. 248 (1982), 333-335.
15. M.A. Raskind, C.H. Sadowsky, W.R. Sigmund, P.J. Beitler and S.B. Auster, Effect of tacrine on language, praxis, and noncognitive behavioural problems in Alzheimer disease, Arch. Neurol. 54 (1997), 836-840.
16. B. Reisberg, S.H. Ferris, G. Steinberg, E. Shulman, M.J. DeLeon and E. Sinaiko, Longitudinal study of dementia patients and aged controls, in: Special research methods for gerontology, M.P. Lawton and A.R. Herzog, eds, NY Baywood, Amityville, 1989, pp. 195-231.
17. B. Reisberg, L. Schneider, R. Doody, R. Anand, H. Feldman, H. Haraguchi, R. Kumar, U. Lucca, C.A. Mangone, E. Mohr, J.C. Morris, S. Rogers and T. Sawada, Clinical global measures of dementia: position paper from the international Working Group on Harmonization of Dementia Drug Guidelines, Alzheimer Dis. Assoc. Disord. 11(suppl 3) (1997), 8-18.
18. M. Rösler, R. Anand, A. Cicin-Sain, S. Gauthier, Y. Agid, P. Dal-Bianco, H.B. Stähelin, R. Hartman, M. Gharabawi and B303 Exelon Study Group, Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial, Br. Med. J. 318 (1999), 633-638.
19. P.J. Whitehouse, D.L. Price, A.W. Clark J.T. Coyle and M.R. DeLong, Alzheimer Disease: evidence for selective loss of cholinergic neurons in the nucleus basalis, Ann. Neurol. 10 (1981), 122-126.